These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 22226771)

  • 1. Drug targeting systems for inflammatory disease: one for all, all for one.
    Crielaard BJ; Lammers T; Schiffelers RM; Storm G
    J Control Release; 2012 Jul; 161(2):225-34. PubMed ID: 22226771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug delivery strategies in the therapy of inflammatory bowel disease.
    Lautenschläger C; Schmidt C; Fischer D; Stallmach A
    Adv Drug Deliv Rev; 2014 May; 71():58-76. PubMed ID: 24157534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biodegradable microspheres targeting mucosal immune-regulating cells: new approach for treatment of inflammatory bowel disease.
    Nakase H; Okazaki K; Tabata Y; Chiba T
    J Gastroenterol; 2003 Mar; 38 Suppl 15():59-62. PubMed ID: 12698874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers.
    Dörner T; Kinnman N; Tak PP
    Pharmacol Ther; 2010 Mar; 125(3):464-75. PubMed ID: 20097226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PI3K isoforms as drug targets in inflammatory diseases: lessons from pharmacological and genetic strategies.
    Harris SJ; Foster JG; Ward SG
    Curr Opin Investig Drugs; 2009 Nov; 10(11):1151-62. PubMed ID: 19876783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases.
    Taylor PC
    Curr Opin Pharmacol; 2010 Jun; 10(3):308-15. PubMed ID: 20172761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-6 as a therapeutic target in candidate inflammatory diseases.
    Nishimoto N
    Clin Pharmacol Ther; 2010 Apr; 87(4):483-7. PubMed ID: 20182422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Considerations for the sensible use of rodent models of inflammatory disease in predicting efficacy of new biological therapeutics in the clinic.
    Arnett HA; Viney JL
    Adv Drug Deliv Rev; 2007 Sep; 59(11):1084-92. PubMed ID: 17804112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liposomal corticosteroids for the treatment of inflammatory disorders and cancer.
    Ozbakir B; Crielaard BJ; Metselaar JM; Storm G; Lammers T
    J Control Release; 2014 Sep; 190():624-36. PubMed ID: 24878183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Broad spectrum immune monitoring in immune-mediated inflammatory disorders.
    't Hart BA; Heije K
    Drug Discov Today; 2005 Oct; 10(20):1348-51. PubMed ID: 16253871
    [No Abstract]   [Full Text] [Related]  

  • 12. [Drug delivery strategies for targeted treatment of inflammatory bowel disease].
    Lautenschläger C; Schmidt C; Lange K; Stallmach A
    Z Gastroenterol; 2015 Mar; 53(3):226-34. PubMed ID: 25723326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting IKKβ for the treatment of rheumatoid arthritis.
    Bamborough P; Morse MA; Ray KP
    Drug News Perspect; 2010 Oct; 23(8):483-90. PubMed ID: 21031164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ACTH: The forgotten therapy.
    Montero-Melendez T
    Semin Immunol; 2015 May; 27(3):216-26. PubMed ID: 25726511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted drug-delivery approaches by nanoparticulate carriers in the therapy of inflammatory diseases.
    Ulbrich W; Lamprecht A
    J R Soc Interface; 2010 Feb; 7 Suppl 1(Suppl 1):S55-66. PubMed ID: 19940000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Drug delivery system of anti-inflammatory and anti-rheumatic drugs].
    Kawai S
    Nihon Rinsho; 1998 Mar; 56(3):782-7. PubMed ID: 9549373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymer-drug conjugates in inflammation treatment.
    Koziolová E; Venclíková K; Etrych T
    Physiol Res; 2018 Oct; 67(Suppl 2):S281-S292. PubMed ID: 30379550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic benefit of PDE4 inhibitors in inflammatory diseases.
    Dastidar SG; Rajagopal D; Ray A
    Curr Opin Investig Drugs; 2007 May; 8(5):364-72. PubMed ID: 17520865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Galenic aspects and therapy of chronic inflammatory bowel diseases. Introduction].
    Schölmerich J
    Med Klin (Munich); 1999 Feb; 94 Suppl 1():3. PubMed ID: 10194939
    [No Abstract]   [Full Text] [Related]  

  • 20. Leukocyte and endothelial cell adhesion molecules as targets for therapeutic interventions in inflammatory disease.
    Ulbrich H; Eriksson EE; Lindbom L
    Trends Pharmacol Sci; 2003 Dec; 24(12):640-7. PubMed ID: 14654305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.